tucatinib,cg0070,pembrolizumab,trastuzumab deruxtecan,vemurafenib,pertuzumab,atezolizumab,vismodegib,alectinib,cobimetinib,pf-06801591,trastuzumab emtansine,trastuzumab,lapatinib,ruxolitinib
daiichi sankyo,astrazeneca,seagen,merck,kissei,cg oncology,novartis,incyte,pfizer,roche
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'core i', 't-dxd', 'tucatinib']
 discussant lower dose t-dxd (5.4 mg/kg) winner in #her2 amplified #mcrc, favors dual her2 1st (tucatinib) then adc given activity in prior her2-treated &amp; ras mt her2+ mcrc &amp; immunoscore ic appears to be promising predictor of tumor immunogenicity #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope